Our vision is to identify and genetically validate novel, disease-relevant drug targets.
We have developed a proprietary 3D multi-omics platform and cell type-specific atlas, which have made it possible to unlock decades’ worth of genomic data, collected from tens of thousands of subjects, to connect genetic variants to disease-driving genes across the entire genome.
